Oxford Biomedica (LON:OXB) Reaches New 12-Month High – Should You Buy?

Oxford Biomedica plc (LON:OXB)’s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as GBX 693 and last traded at GBX 691, with a volume of 127693 shares changing hands. The stock had previously closed at GBX 663.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group reiterated a “buy” rating and set a GBX 451 price target on shares of Oxford Biomedica in a research note on Tuesday, October 7th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Oxford Biomedica currently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 558.

Oxford Biomedica Stock Performance

The company has a market cap of £817.25 million, a PE ratio of -18.72 and a beta of 1.09. The stock has a 50 day simple moving average of GBX 621.67 and a two-hundred day simple moving average of GBX 539.07. The company has a debt-to-equity ratio of 166.48, a current ratio of 2.35 and a quick ratio of 1.67.

Insider Buying and Selling

In other Oxford Biomedica news, insider Heather Preston purchased 6,175 shares of Oxford Biomedica stock in a transaction that occurred on Monday, October 20th. The stock was purchased at an average price of GBX 593 per share, for a total transaction of £36,617.75. 34.83% of the stock is currently owned by company insiders.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.